Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnWeb3SquareMore
Trade
Spot
Buy and sell crypto with ease
Margin
Amplify your capital and maximize fund efficiency
Onchain
Going Onchain, without going Onchain!
Convert
Zero fees, no slippage
Explore
Launchhub
Gain the edge early and start winning
Copy
Copy elite trader with one click
Bots
Simple, fast, and reliable AI trading bot
Trade
USDT-M Futures
Futures settled in USDT
USDC-M Futures
Futures settled in USDC
Coin-M Futures
Futures settled in cryptocurrencies
Explore
Futures guide
A beginner-to-advanced journey in futures trading
Futures promotions
Generous rewards await
Overview
A variety of products to grow your assets
Simple Earn
Deposit and withdraw anytime to earn flexible returns with zero risk
On-chain Earn
Earn profits daily without risking principal
Structured Earn
Robust financial innovation to navigate market swings
VIP and Wealth Management
Premium services for smart wealth management
Loans
Flexible borrowing with high fund security
Parataxis Acquires Bridge Biotherapeutics for Bitcoin Treasury Transformation

Parataxis Acquires Bridge Biotherapeutics for Bitcoin Treasury Transformation

Coinlive2025/06/21 16:56
By:Coinlive
Key Points:

  • Parataxis acquires Bridge Biotherapeutics, Edward Chin joins the board.
  • Creating first KOSDAQ-listed Bitcoin treasury platform.
  • Bridge Bio continues biotech operations under existing leadership.
Parataxis Acquires Bridge Biotherapeutics for Bitcoin Treasury Transformation

Parataxis Holdings has announced the acquisition of South Korea-listed Bridge Biotherapeutics for KRW 25 billion, targeting a transformation into a Bitcoin-native treasury service.

This acquisition illustrates a strategic shift in bridging biotech operations with cryptocurrency treasury services, with immediate influence on Bitcoin exposure in Korean public markets.

Parataxis to Acquire Bridge Biotherapeutics for Bitcoin Treasury Expansion Parataxis Holdings’ move to acquire Bridge Biotherapeutics involves a KRW 25 billion investment. By transforming Bridge Biotherapeutics into Parataxis Korea , the company will pivot towards a Bitcoin-native treasury service. This marks a notable shift for the biotech firm—which will remain listed on KOSDAQ—and opens a new chapter in its operational focus.

Leading the transition, Parataxis Holdings’ CEO Edward Chin will join Bridge Biotherapeutics’ board. Meanwhile, Partner Andrew Kim will assume the role of CEO for the new entity. This restructuring aims to serve Korean institutional demand for Bitcoin.

“We are excited to transition Bridge Biotherapeutics into Parataxis Korea to pioneer a Bitcoin-native treasury service for institutions.” — Edward Chin, Founder and CEO of Parataxis Holdings

Immediate market effects of this transaction center on Bitcoin, as the new company focuses solely on this cryptocurrency as a treasury asset. Traditional market structures in Korea will witness a new player with this unique approach.

The strategic move aligns with global precedents like those of MicroStrategy, but as an unprecedented step in Korea, it signifies a novel route for KOSDAQ-listed entities. No immediate effects on Ethereum or other altcoins have been reported.

Regulatory approval is pending with a Bridge Biotherapeutics shareholder vote set for August 2025. Broader market responses are pinned on this outcome, ensuring institutional and public interest is kept at the forefront. Historical trends suggest financial markets might observe increased institutional BTC activities.

0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Locked for new tokens.
APR up to 10%. Always on, always get airdrop.
Lock now!